secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2023-07-14T23:59:59+00:00
Accession:  0001193125-23-187257
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Aeglea BioTherapeutics transfers listing to Nasdaq Capital Market to address bid price deficiency
--------------------------------------------------------------------------------

- Received notice of Minimum Bid Price non-compliance on Jan 13, 2023; initial grace period ended July 12, 2023.
- Nasdaq approved transfer to Capital Market effective July 14, 2023; stock symbol remains AGLE.
- Granted additional 180-day grace period until Jan 8, 2024 to regain $1.00 bid price for 10 consecutive days.
- Company intends to implement reverse stock split (approved by stockholders on June 6, 2023) to regain compliance.
- Failure to regain compliance by Jan 8, 2024 could result in delisting; may appeal to Nasdaq Hearings Panel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000119312523187257/0001193125-23-187257-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000119312523187257/d489147d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-187257

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer